View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
May 6, 2021

North America’s medical devices industry saw a rise of 34.83% in cross border deal activity in Q1 2021

Led by $635m acquisition of Capsule Technologies, North America’s medical devices industry saw a rise of 34.83% in cross border deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 60 cross border deals worth $2.25bn were announced for the region during Q1 2021, against the last four-quarter average of 44.50 deals.

Of all the deal types, venture financing saw most activity in Q1 2021 with 31 deals, representing a 51.7% share for the region.

In second place was M&A with 23 deals, followed by private equity deals with six transactions, respectively capturing a 38.3% and 10% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in North America’s medical devices industry with $1.16bn, while venture financing and private equity deals totalled $715.46m and $369.67m, respectively.

North America medical devices industry cross border deals in Q1 2021: Top deals

The top five medical devices cross border deals accounted for a 53% share of the overall value during Q1 2021.

The combined value of the top five cross border deals stood at $1.19bn, against the overall value of $2.25bn recorded for the quarter.

The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:

1) Koninklijke Philips’ $635m acquisition of Capsule Technologies

2) The $240m acquisition of Alydia Health by Organon

3) Fidelity Management & Research and T Rowe Price Associates’ $115m private equity deal with Kardium

4) The $110m acquisition deal with 7D Surgical by SeaSpine

5) Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans’ venture financing with Hyperfine Research for $90m.

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network